Current cancer immune-therapies rely on antibodies or engineered cells targeting tumour-specific targets. Although they are highly successful in small populations of patients with specific cancer types, these treatments are complicated to implement and very costly.
Our research program aims to overcome these problems by developing treatments using drug-like molecules to effectively induce a phenomenon known as immunogenic cell death (ICD). The arising treatments should be applicable to a broad range of cancer types, but we are focused on development of intra-tumour injections for treatment of relapsed and refractory cervical cancer.
This project will use the proprietary Metaplex technology to prepare combinations of candidate compounds and copper in liposomes, in order to develop clinically relevant novel anticancer agents that are currently not suitable for pharmacological development.
Development of the Metaplex Immuno-Oncology Platform
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.